AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01545947
Drug: CC-223, erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose escalation: Combination doses start with 15 mg CC-223 and 100 mg erlotinib, or 15 mg CC-223 and 150 mg erlotonib, administered in 28-day cycles. Combination dose levels increase sequentially using predefined regimens until non-tolerated dose levels are established and a maximum tolerated dose combination has been identified for further study.~Dose expansion: The maximum tolerated doses are evaluated further for evidence of preliminary efficacy
Trial: NCT00203047
Drug: Glatiramer Acetate
RxNorm normalized name: Glatiramer Acetate
DrugBank: Glatiramer (DB05259)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20mg glatiramer acetate (GA) administered by daily subcutaneous injections
Trial: NCT00203047
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone 1250 mg taken daily
Trial: NCT03057847
Drug: Sofosbuvir/Velpatasvir
RxNorm normalized name: SOFOSBUVIR/VELPATASVIR
DrugBank: Sofosbuvir (DB08934)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sofosbuvir/Velpatasvir One tablet (400 mg of sofosbuvir and 100 mg of velpatasvir) taken orally once daily for 12 weeks in the postpartum period
Trial: NCT00662597
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00662597
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT03396068
Drug: NRX-101
RxNorm normalized name: NRX-1074
DrugBank: INBRX-101 (DB18384)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NRX-101, a fixed dose combination of D-cycloserine+lurasidone will be given twice a day by mouth
Trial: NCT03396068
Drug: Lurasidone HCl
RxNorm normalized name: lurasidone HCl
DrugBank: Lurasidone (DB08815)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lurasidone HCl will be given twice a day by mouth
Trial: NCT00470197
Drug: alvocidib
RxNorm normalized name: Alvocidib
DrugBank: Alvocidib (DB03496)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00470197
Drug: cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00470197
Drug: mitoxantrone hydrochloride
RxNorm normalized name: Mitoxantrone Hydrochloride
DrugBank: Mitoxantrone (DB01204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01908751
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01908751
Drug: Vitamin D Placebo
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04435392
Drug: Jaktinib Hydrochloride Cream
RxNorm normalized name: diphenhydramine hydrochloride Topical Cream
DrugBank: Jaktinib (DB17545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects in each group were scheduled to give the drug for 8 weeks.
Trial: NCT01333085
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01333085
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01967069
Drug: Vehicle Spray
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02410005
Drug: Losartan
RxNorm normalized name: Losartan
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00025077
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00025077
Drug: thiotepa
RxNorm normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00506805
Drug: SNX-5422
RxNorm normalized name: SNX-5422
DrugBank: SNX-5422 (DB06070)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dose escalated, tablets every other day; undetermined duration until disease progression
Trial: NCT00450320
Drug: sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The target rapamycin trough level will be 5-10 ng/mL. The initial dose will be dependent upon the type of HAART regimen. Subjects will continue on study protocol for six cycles as long as their KS is stable or continuing to respond to study medication. Treatment will be extended for up to six additional cycles if the subject has met criteria for a response. Subjects with no more than stable disease will have treatment discontinued after six cycles. Protocol treatment will be discontinued if the subject develops tumor progression, unacceptable toxicity or develops one of the protocol-defined reasons for treatment discontinuation at any time during the study.
Trial: NCT02952196
Drug: drug administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: administering drug to patient with amphetamine addiction
Trial: NCT02205775
Drug: Atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 80 + 40 mg pre PCI
Trial: NCT02205775
Drug: Ezetimibe
RxNorm normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10 mg twice before PCI (+ 5 mg rosuvastatin)
Trial: NCT02443103
Drug: Guanabenz acetate
RxNorm normalized name: Guanabenz Acetate
DrugBank: Guanabenz (DB00629)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01458990
Drug: Omeprazole
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20mg PO BID for 20 days
Trial: NCT01336049
Drug: Nimotuzumab
RxNorm normalized name: nimotuzumab
DrugBank: Nimotuzumab (DB06192)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimotuzumab 200mg/week
Trial: NCT00822770
Drug: Plerixafor
RxNorm normalized name: Plerixafor
DrugBank: Plerixafor (DB06809)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phase I: Starting dose of 0 (escalating doses 80, 160, 240 mcg/kg) given daily subcutaneously in abdomen for 4 doses.~Phase II: Maximum Tolerated Dose (MTD) as determined in Phase I
Trial: NCT00822770
Drug: Filgrastim
RxNorm normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dose of 10 mcg/kg subcutaneous injection beginning on day -9 daily for 6 days.
Trial: NCT00822770
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose of 40 mg/m\^2 beginning on Day -6 for four consecutive days.
Trial: NCT00822770
Drug: Busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dose of 130 mg/m\^2 for four consecutive days, immediately after completion of Fludarabine.
Trial: NCT00822770
Drug: ATG (Thymoglobulin)
RxNorm normalized name: ATGAM
DrugBank: Antilymphocyte immunoglobulin (horse) (DB09312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose(s) of 0.5 mg/kg on day -3; of 1.5 mg/kg on day -2; and of 2 mg/kg on day -1. Given only to patients with unrelated donors.
Trial: NCT02993523
Drug: Azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Solution for subcutaneous or intravenous administration.
Trial: NCT02993523
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tablet
Trial: NCT00790205
Drug: Sitagliptin
RxNorm normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sitagliptin, one 50 mg or one 100 mg tablet (dose dependant on renal function) orally, once daily.
Trial: NCT01442272
Drug: Paricalcitol: Zemplar®
DrugBank: Paricalcitol (DB00910)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paricalcitol (Zemplar®) oral capsule , 1 mcg (1 capsule)each 24 hours during 12 months
Trial: NCT01472913
Drug: Fibrin sealant
RxNorm normalized name: FIBRIN SEALANT
DrugBank: Fibrin (DB16604)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibrin sealant is applied on the surfaces of bone and soft tissue of surgery after placement of the prothesis due to the randomised knee.
Trial: NCT01472913
Drug: Saline water
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Same procedure to the opposite knee (the same patient) performed with sprayed saline water (placebo).
Trial: NCT00594698
Drug: PB127 for injectable suspension
RxNorm normalized name: PB127
DrugBank: PB127 (DB06208)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.175 mg/kg diluted in 150 mL 5% Dextrose for Injection in glass bottles, to be administered as a single continuous infusion during image acquisition. Infusion time not to exceed 60 minutes
Trial: NCT01296555
Drug: Fulvestrant
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants will receive fulvestrant 500 milligrams (mg) via intramuscular injection (as per package insert or Summary of Product Characteristics \[SmPC\]) on Days 1 and 15 of Cycle 1, then on Day 1 of each subsequent cycle, until disease progression (Cycle length: 28 days).
Trial: NCT01296555
Drug: GDC-0032
RxNorm normalized name: calcium carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive GDC-0032 at escalating (Phase I, Stage 1) or fixed (Phase II and Phase I, Stage 2) doses until disease progression. Cycle 1 may be 35 days in length to allow for a 7-day washout following the initial dose; thereafter, GDC-0032 will be administered orally once daily in 28-day cycles.
Trial: NCT01296555
Drug: Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive letrozole 2.5 mg orally (as per Package Insert or SmPC) once daily in 28-day cycles until disease progression.
Trial: NCT00664703
Drug: Lobeline sulfate
RxNorm normalized name: lobeline sulfate
DrugBank: Lobeline (DB05137)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each laboratory day, participants will receive one capsule containing either methylphenidate HCl (15 or 30 mg) or placebo, and one sublingual tablet containing either lobeline (7.5, 15, or 30 mg) or placebo.
Trial: NCT00664703
Drug: Methylphenidate HCl
RxNorm normalized name: methylphenidate HCl
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Each laboratory day, participants will receive one capsule containing either methylphenidate HCl (15 or 30 mg) or placebo, and one sublingual tablet containing either lobeline (7.5, 15, or 30 mg) or placebo.
Trial: NCT01630590
Drug: Cabozantinib
RxNorm normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Starting dose of 60 mg by mouth every day of a 21 day cycle.
Trial: NCT01296555
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive midazolam 5 mg (as per Package Insert or SmPC) in hydrochloride syrup on Days 1 and 16 of Cycle 1.
Trial: NCT00480064
Drug: Lomustine, intermediate dose cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00612118
Drug: azelastine hydrochloride
RxNorm normalized name: Azelastine Hydrochloride
DrugBank: Azelastine (DB00972)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 140mcg
Trial: NCT03219762
Drug: Nabpaclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Chemotherapy will be continued until a maximum of 6 courses or progressive disease or intolerable toxicity or patient refusal. In patients with confirmed and prolonged disease response, clinical benefit and good tolerance to study drug treatment, the investigators can evaluate to continue therapy beyond 6th cycle, after discussion with Principal Investigator (PI) of the study
Trial: NCT01017653
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Irinotecan: for those patients on an enzyme-inducing anti-epileptic drug (EIAED), irinotecan will be dosed at 340 mg/m2 every other week. For those not on an EIAED, irinotecan will be dosed at 125 mg/m2. Treatment on both drugs will continue until tumor progression or unacceptable toxicity.
Trial: NCT01424462
Drug: A
RxNorm normalized name: Ac
DrugBank: Actinium (DB12860)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose treatment IR formulation
Trial: NCT01424462
Drug: B
RxNorm normalized name: Bk
DrugBank: Berkelium (DB12993)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low Extended release single dose
Trial: NCT01424462
Drug: C
RxNorm normalized name: Ac
DrugBank: Fosdenopterin (DB16628)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medium extended release formulation
Trial: NCT01424462
Drug: D
RxNorm normalized name: D
DrugBank: Rosomidnar (DB17154)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High extended release rate single dose
Trial: NCT01031628
Drug: Imatinib mesylate
RxNorm normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 400 mg daily. Number of cycles: until disease progression or unacceptable toxicity develops
Trial: NCT01031628
Drug: Imatinib mesylate
RxNorm normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 600 or 800 mg daily. Number of cycles: until disease progression or unacceptable toxicity develops
Trial: NCT01031628
Drug: Imatinib mesylate
RxNorm normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 400, 600 or 800 mg daily. Number of cycles: until disease progression or unacceptable toxicity develops
Trial: NCT03080493
Drug: Gabapentin 600mg
RxNorm normalized name: GABAPENTIN 600MG TAB
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gabapentin 600 mg PO (two total doses, thereby lasting duration while osmotic dilators are in place)
Trial: NCT02016209
Drug: nanoparticle albumin-bound paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Neoadjuvant chemotherapy of nanoparticle albumin-bound paclitaxel in stage Ⅱ B and IIIA non-small cell lung cancer
Trial: NCT01017653
Drug: Panitumumab
RxNorm normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Panitumumab, 6 mg/kg, as an intravenous infusion every other week. Treatment on both drugs will continue until tumor progression or unacceptable toxicity.
Trial: NCT00005871
Drug: rubitecan
RxNorm normalized name: Rubitecan
DrugBank: Rubitecan (DB06159)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03450499
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: the analgesic affects of ketamine will be compared between the experimental and placebo group.
Trial: NCT00303238
Drug: Rose hips extract + blueberry/blackberry extract + resveravine
DrugBank: Blackberry (DB10628)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01055236
Drug: hydroxyzine
RxNorm normalized name: Hydroxyzine
DrugBank: Hydroxyzine (DB00557)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75 mg of hydroxyzine orally as premedication drugs at least half an hour before operation.
Trial: NCT01712061
Drug: PF-04634817
RxNorm normalized name: PF-04634817
DrugBank: PF-04634817 (DB14955)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three or four tablets (50mg) daily for 12 weeks, depending on baseline renal function
Trial: NCT00211302
Drug: aripiprazole
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 10-15 mg/day; if needed, dosage may be increased to 30 mg/day after week 2; maintenance 15 mg/day; periodically reassessed
Trial: NCT01937975
Drug: Grazoprevir
RxNorm normalized name: Grazoprevir
DrugBank: Grazoprevir (DB11575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg oral tablet administered once a day for 10 days
Trial: NCT01937975
Drug: Elbasvir
RxNorm normalized name: Elbasvir
DrugBank: Elbasvir (DB11574)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg oral tablet administered once a day for 10 days
Trial: NCT02638597
Drug: Gemfibrozil
RxNorm normalized name: Gemfibrozil
DrugBank: Gemfibrozil (DB01241)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: FDA Approved Drug(s)/Biologic(s) (study use is not an FDA-approved use)
Trial: NCT00431613
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 75 mg/m2 IV on day 8 every 3 weeks for 2 cycles
Trial: NCT00431613
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine 1100 mg/m2 on days 1 and 8 every 3 weeks for 2 cycles
Trial: NCT00431613
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin 6AUC IV on day 1 every 3 weeks for 3 cycles
Trial: NCT00431613
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 75mg/m2 IV on day 1 for 3 cycles
Trial: NCT02251236
Drug: Stribild
RxNorm normalized name: Stribild
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: To be administered orally, once daily with food.
Trial: NCT02251236
Drug: Genvoya
RxNorm normalized name: Genvoya
DrugBank: Emtricitabine (DB00879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: To be administered orally, once daily with food.
Trial: NCT00965497
Drug: escitalopram
RxNorm normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After confirmation of diagnoses and safety screening escitalopram will be started at 10 mg per day and augmented weekly in 10 mg per day increments, the maximum dose being 20 mg per day. The dose will be titrated upward or downward based on clinical response and tolerability. No other psychotropic medications will be permitted during the study. Medications for coexisting medical problems (e.g. hypertension) will be permitted. Study visits will include weekly visits for first 2 weeks and biweekly visits for next 6 weeks. Medications will be dispensed weekly or biweekly and the participants will be followed for 8 weeks.
Trial: NCT01751113
Drug: fluticasone propionate/salmeterol
RxNorm normalized name: fluticasone propionate/salmeterol 100/50 MCG/INHAL Dry Powder Inhaler, 14 Blisters
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 250mcg fluticasone + 50 mcg salmeterol, twice daily 4 week treatment in each treatment sequence (crossover design)
Trial: NCT01751113
Drug: tiotropium bromide
RxNorm normalized name: Tiotropium Bromide
DrugBank: Tiotropium (DB01409)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 18 mcg tiotropium bromide, once daily 4 week treatment in each treatment sequence (crossover design)
Trial: NCT01751113
Drug: fluticasone propionate/salmeterol plus tiotropium bromide
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 250mcg fluticasone + 50 mcg salmeterol, twice daily plus 18 mcg tiotropium bromide, once daily 4 week treatment in each treatment sequence (crossover design)
Trial: NCT00325936
Drug: Cilnidipine
RxNorm normalized name: Cilnidipine
DrugBank: Cilnidipine (DB09232)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10\~20mg, qd, po for 3 months or 12 months.
Trial: NCT01551368
Drug: Nimodipine
RxNorm normalized name: Nimodipine
DrugBank: Nimodipine (DB00393)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nimodipine 30 mg tablets will be self-administered by the subjects every 6 hours starting on the day that the ultrasound criterion for hCG triggering is met. The tablets will be taken for two days or until an LH surge is detected, whichever comes first. If no LH surge by 2 days, the hCG trigger (250 micrograms recombinant hCG) will be given followed by intrauterine insemination (IUI)in 40 hours. If the LH surge is detected, hcg will be given immediately and two IUIs will be performed 24 hours apart.
Trial: NCT03327272
Drug: Methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Injection of 80mg Depomedrol injectable suspension at surgical site prior to incision closure
Trial: NCT03327272
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administration of saline at surgical site prior to incision closure
Trial: NCT00303238
Drug: Rose hips extract + blueberry/blackberry extract + Aframomum melegueta extract
DrugBank: Blackberry (DB10628)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05146089
Drug: Oral Bosentan 62.5 mg
DrugBank: Bosentan (DB00559)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prior to completion of visit 2, male subjects will consume 62.5 mg twice daily for 3 days as well as the morning of the study visit (7 pills) at home and experimental sessions will be performed 3 hours after oral intake of the final dose.
Trial: NCT02283476
Drug: Endostar continuous intravenous infusion
RxNorm normalized name: Ivy Dry Super Continuous Spray
DrugBank: Endostar (DB11727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endostar,7.5mg/m2, continuous intravenous infusion for 14 days each cycle, 21 days as one cycle, 4 cycles in total.
Trial: NCT02283476
Drug: Endostar routine intravenous infusion
RxNorm normalized name: Menostar
DrugBank: Endostar (DB11727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endostar,7.5mg/m2, routine intravenous infusion 3-4 hours daily each cycle,21 days as one cycle, 4 cycles in total